Researcher
Pieter Annaert
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Department of Pharmaceutical and Pharmacological Sciences (Department)
Responsible
From1 Aug 2020 → Today - Drug Delivery and Disposition (Division)
Member
From1 Oct 2005 → Today
Projects
1 - 10 of 33
- Investigating current gaps in time-dependent inhibition (TDI) and induction drug-drug interactions (DDIs). A focus on CYP3A4 and non-CYPs drug metabolizing enzymes (DMEs).From24 May 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Improved clearance prediction using ex vivo and new in silico tools to bridge the in vitro to in vivo extrapolation (IVIVE) gapFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Investigation of bidirectional pharmacokinetic drug-drug interaction between vicagrel, a novel analogue for the antiplatelet drug clopidogrel, and atorvastatinFrom15 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Design and development of FabV inhibitors as a new class of antibacterials for pathogenic Gram-negative bacteriaFrom1 Oct 2021 → TodayFunding: Baekeland
- Predicting exposure of neonates to maternal medicines via breastfeedingFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Model-informed drug development: application to drug-induced cholestasisFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Drug exposure through lactation: providing neonatal physiology to improve pharmacokinetic predictionsFrom21 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Drug Design and Development: From Target to MarketFrom7 Jun 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Integrated PK/PM Model-based Medication Dosing Assist App(lication) in KlinischWerkStation (KWS). Validation Studies of Tacrolimus in (Solid) Organ TransplantationFrom1 Jan 2021 → 31 Dec 2023Funding: IOF - technology validation in lab
- In vitro and in silico investigation of pharmacokinetics in neonates undergoing therapeutic hypothermiaFrom26 Nov 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
201 - 210 of 253
- Stability of therapeutic albumin solutions used for molecular adsorbent recirculating system-based liver dialysis(2012)
Authors: Tom De Bruyn, Björn Meijers, Pieter Evenepoel, Ludo Willems, Patrick Augustijns, Pieter Annaert
Pages: 29 - 41 - Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3(2011)
Authors: Tom De Bruyn, Sarinj Fattah, Patrick Augustijns, Pieter Annaert
Pages: 5018 - 5030 - Preventing release in the acidic environment of the stomach via occlusion in ordered mesoporous silica enhances the absorption of poorly soluble weakly acidic drugs(2011)
Authors: Michiel Van Speybroeck, Randy Mellaerts, Johan Martens, Jan Van Humbeeck, Pieter Annaert, Guy Van den Mooter, Patrick Augustijns
Pages: 4864 - 4876 - Comparison between 2-hydroxypropyl-β-cyclodextrin and 2-hydroxylpropyl-γ-cyclodextrin for inclusion complex formation with danazol(2011)
Authors: Thao Do Thi, Koen Nauwelaerts, Michiel Van Speybroeck, Jan Vermant, Patrick Augustijns, Pieter Annaert, Johan Martens, Jan Van Humbeeck, Guy Van den Mooter
Pages: 137 - 147 - Comparison between 2-hydroxypropyl-β-cyclodextrin and 2-hydroxylpropyl-γ-cyclodextrin for inclusion complex formation with danazol(2011)
Authors: Thao Do Thi, Koen Nauwelaerts, Luc Baudemprez, Michiel Van Speybroeck, Jan Vermant, Patrick Augustijns, Pieter Annaert, Jan Van Humbeeck, Guy Van den Mooter
Pages: 137 - 147 - Influence of Drug Transport Proteins on the Pharmacokinetics and Drug Interactions of HIV Protease Inhibitors(2011)
Authors: Pieter Annaert
Pages: 3636 - 3654 - Intestinal drug solubility estimation based on simulated intestinal fluids: Comparison with solubility in human intestinal fluids(2011)
Authors: Sarah Clarysse, Joachim Brouwers, Jan Tack, Pieter Annaert, Patrick Augustijns
Pages: 260 - 269 - Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis(2011)
Authors: Isabel Spriet, Wouter Meersseman, Pieter Annaert, Jan de Hoon, Ludo Willems
Pages: 753 - 755 - The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate(2011)
Authors: Thao Do, Michiel Van Speybroeck, Raf Mols, Pieter Annaert, Jan Van Humbeeck, Jan Vermant, Patrick Augustijns, Guy Van den Mooter
Pages: 118 - 124 - The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate(2011)
Authors: Michiel Van Speybroeck, Pieter Annaert, Johan Martens, Jan Van Humbeeck, Jan Vermant, Patrick Augustijns, Guy Van den Mooter
Pages: 118 - 124